Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10864323 | 0.80 | AKT1 (0.46) | AKT1KCNH2ACACBMETLMNA | |
| SCHEMBL6671851 | 0.78 | AKT1 (0.45) | AKT1ROCK2KCNH2ACACBLMNA | |
| SCHEMBL7981853 | 0.78 | AKT1 (0.38) | AKT1KCNH2METLMNANOS2 | |
| SCHEMBL7981642 | 0.75 | AKT1 (0.34) | AKT1METNOS2CYP2C8CYP2D6 | |
| SCHEMBL7879844 | 0.74 | — | — | |
| SCHEMBL84454 | 0.72 | — | — | |
| SCHEMBL8175926 | 0.72 | KCNH2 (0.34) | AKT1ROCK2KCNH2ACACBLMNA | |
| SCHEMBL12464827 | 0.71 | KCNH2 (0.41) | AKT1KCNH2LMNAAPEX1PMP22 | |
| SCHEMBL7999488 | 0.71 | AKT1 (0.32) | AKT1CYP2C8CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL19333946 | 0.71 | KCNH2 (0.37) | AKT1KCNH2ACACBLMNAAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003654-B2 | N-glycinsulfonamide derivatives and uses as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-08-23 | — | — | US | disclosed |
| US-20090275588-A1 | NOVEL SULFONAMIDE COMPOUNDS | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-11-05 | — | — | US | disclosed |
| EP-2007717-A1 | NOVEL SULFONAMIDE COMPOUNDS | Actelion Pharmaceuticals Ltd. (CH) | 2008-12-31 | — | — | EP | disclosed |
| WO-2007116374-A1 | NOVEL SULFONAMIDE COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275588-A1 | NOVEL SULFONAMIDE COMPOUNDS | HCRTR2, HCRTR1, NPSR1 | AKT1 3692/4885ROCK2 3449/4885KCNH2 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.